Help us fund research
that is changing lives


The MS Bioscreen

The scientists and clinicians in our UCSF Multiple Sclerosis (MS) Group, led by our Department Chair Dr. Stephen Hauser and Pierre-Antoine Gourraud, created “The Multiple Sclerosis BioScreen”, a milestone in the delivery of precision medicine for a chronic disease. This BioScreen is an MS data infrastructure platform that, when connected to a digital front end interface, visually represents the course of an individual with MS, includes clinical, imaging, and biomarker information, frames this course within the context of a large cohort of patients treated according to contemporary standards and followed rigorously for >10 years, contextualizes and predicts the clinical course, informs more precise clinical decisions, and empowers patients to participate more actively in their clinical care (Click here to watch a demonstration). Essentially, it functions as a growth curve for MS.

Our work received key support from PCORI and the Conrad N. Hilton Foundation.

If you would like more information on this tool, please contact Riley Bove, MD.

Representative image from the MS BioScreen (with all patient identifiers altered)

Work In Progress


A clinical trial addressing its effect on the patient-doctor relationship and on clinical decision-making began in February 2016. Preliminary results from a pilot trial (as well as over 70 formal meetings since 2013 with MS stakeholders and interested parties) suggest that both patients and providers enthusiastically embrace openly accessible tools to visualize individual health trajectories, contextualize these against a “virtual caseload” and guide decision making in an evidence-based manner (analogous to a “second opinion”).

Key personnel: Riley Bove, Priya Garcha


In addition to research patients, the MS BioScreen now includes also data from 4,000+ MS patients clinically followed at UCSF. Patients have been algorithmically identified from the UCSF Electronic Medical Records system. Operating only under strict ethical guidelines, patients’ demographic and treatment information, laboratory tests results and MS specific metrics have been extracted and uploaded to the MS BioScreen.

Key personnel: Vincent Damotte


A high-throughput imaging infrastructure is being developed to move MS exams from MRI scanners and PACS, through automated deidentification and processing pipelines and into the cloud where they can be access by MSBioscreen client applications. This infrastructure lays the ground work for developing advanced analysis pipelines to derive scalar imaging attributes that, together with clinical and other biomarker data in the MS BioScreen, can be mined and used to advance MS research.

Key personnel: Jason Crane, Beck Olson


We are in the process of developing an Open Access, web-based version of the MS BioScreen available to any patient, caregiver or clinician with a Web browser. This would allow any user anywhere (within or beyond highly specialized academic care settings) the opportunity to enter data on their condition, obtain a richly contextualized digestible and actionable predictive output, free of commercial interest, and participate in a shared decision making process.

We are pleased to have been selected by the joint UCSF-UC Berkeley Masters in Translation Medicine program as a Capstone Project, and current 2016-2017 MTM scholars will be actively embedded in our team to participate in the development of the Open MS BioScreen.

Key personnel: Team


Combining the wealth of high-quality data with programmatic development and medical expertise, our team is building the algorithms that will power the future of tools at the point of care. We started with our patented 'Personalized Contextualization of Patient Trajectories', and are currently validating machine-learning approaches to prediction of short-term outcomes.

Key personnel: Antoine Lizee, Riley Bove

The Team (Left to right: Tommy Carpenito, Priya Garcha, Antoine Lizee, Adam Santaniello, Vincent Damotte, Beck Olson, Alisha Agrawal, Jason Crane, and Riley Bove)